Join us on Tuesday, March 10 from 1:00pm – 2:00pm EST for part two of our clinical pharmacology 101 webinar series. Nuventra’s Chief Scientific Officer, David Y. Mitchell, Ph.D., will lead the session titled, “The Purpose of Clinical Pharmacology Studies in Drug Development.”
Part two of this series will cover clinical pharmacology fundamentals including:
- Scope and significance
- Why we need clinical pharmacology studies
In general, clinical pharmacology studies are designed to gain understanding regarding the safety, pharmacokinetics (PK), pharmacodynamics (PD), drug interactions, and PK/PD in special populations of new chemical entities (NCEs) or biologics.
Meet the Presenter
David Y. Mitchell, Ph.D.
Chief Scientific Officer
Dr. Mitchell has more than 28 years of leadership experience in clinical pharmacology and pharmacokinetics (PK). His focus is on strategic drug development, protocol design and planning, clinical and nonclinical data analysis/simulation/interpretation, and clinical pharmacology representation at regulatory meetings.